Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

February 26, 2020

Novartis, DNDi to jointly develop LXE408 for visceral leishmaniasis

Novartis has signed a collaboration and licence agreement with the Drugs for Neglected Diseases initiative (DNDi) for the joint development of LXE408 as a new oral drug for the treatment of visceral leishmaniasis.

Novartis, DNDi to jointly develop LXE408 for visceral leishmaniasis